Legal
Filter News
Found 9,664 articles
-
Companies are still developing and refining treatments and preventions for COVID-19, but not all of them are approved or authorized. Here’s a look at the latest COVID-19 news.
-
Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor
7/1/2022
Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company's subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial.
-
As the nation reacts to the overturning of Roe v. Wade, pharma companies must address the changes in demand for drugs and services, all while navigating increasingly muddy legal waters.
-
In addition to patent cases, partnerships and pledging money to global tropical disease efforts, Novartis scored a win on a combo-treatment for solid tumors.
-
Novartis' win in the patent dispute over its drug, Gilenya, was short-lived after a U.S. appeals court reversed its 2020 ruling vs. HEC Pharm's attempt to create a generic version.
-
Enanta filed a patent infringement lawsuit against Pfizer for the latter's alleged use of its proprietary antiviral component in producing the COVID-19 antiviral Paxlovid.
-
Three physicians filed a lawsuit against the FDA alleging the organization acted outside its authority and with their ability to practice medicine by discouraging the use of ivermectin to treat COVID-19.
-
The vote came just over one week after the FTC announced it would probe claims regarding the role the middlemen play in determining retail prices of prescription drugs.
-
Genmab A/S is seeking a new arbitration ruling against Janssen seeking $405 million-plus interest in accrued milestone payments for Darzalex Faspro.
-
Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
6/9/2022
Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s Abbreviated New Drug Application (“ANDA") for a generic deutetrabenazine product.
-
Novo Nordisk and Eli Lilly came under legal scrutiny this week, while BMS forked over $11 million to settle claims over anticompetitive tactics.
-
Novartis has fallen victim to a cyberattack. The Swiss pharma giant’s data was hijacked by a well-known online extortion ring dubbed Industrial Spy.
-
Doctors Sue FDA Over Unlawful Attempts to Prohibit Ivermectin Use
6/2/2022
Boyden Gray & Associates PLLC -- Today, a group of doctors filed a lawsuit against the Department of Health and Human Services, Xavier Becerra in his official capacity as Secretary of Health and Human Services, the Food and Drug Administration, and Robert M. Califf in his official capacity as Commissioner of Food and Administration.
-
Shares of Enochian Biosciences plunged more than 36% after the Justice Department announced company cofounder Serhat Gumrukçu was arrested in a sordid 2018 murder-for-hire scheme.
-
ENOCHIAN BIOSCIENCES INC. INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud
5/26/2022
Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Enochian BioSciences Inc. (“Enochian” or the “Company”) (Nasdaq: ENOB), a company that purports to be a biotechnology company.
-
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application for the Treatment of Behavioral Addictions
5/26/2022
The successful completion of Awakn's behavioral addictions study was announced last week and the data provided from the study was used in the patent filing.
-
Monday, Moderna told a Delaware federal court that it was immune from patent-infringement charges over the COVID-19 vaccine because it supplied the vaccine for a U.S. government effort.
-
Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit over a generic multiple sclerosis drug developed by India-based Natco, Gland Pharma and Mylan.
-
Vanda has again taken legal action against the FDA over its supposed failure to grant tradipant Fast Track designation. In its complaint, Vanda is challenging the FDA’s decision to deny the designation.
-
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity
5/24/2022
Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Journey Medical and Padagis US LLC (“Padagis”) entered into a settlement agreement pertaining to the patents protecting QBREXZA®.